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SARS coronavirus (SARS-CoV) administered intranasally and intratracheally to rhesus, cynomolgus and African Green monkeys (AGM)
replicated in the respiratory tract but did not induce illness. The titer of serum neutralizing antibodies correlated with the level of virus
replication in the respiratory tract (AGMNcynomolgusNrhesus). Moderate to high titers of SARS-CoV with associated interstitial pneumonitis
were detected in the lungs of AGMs on day 2 and were resolving by day 4 post-infection. Following challenge of AGMs 2 months later, virus
replication was highly restricted and there was no evidence of enhanced disease. These species will be useful for the evaluation of the
immunogenicity of candidate vaccines, but the lack of apparent clinical illness in all three species, variability from animal to animal in level
of viral replication, and rapid clearance of virus and pneumonitis in AGMs must be taken into account by investigators considering the use of
these species in efficacy and challenge studies.
Published by Elsevier Inc.
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Severe acute respiratory syndrome (SARS) was recog-
nized in late 2002, and by the end of the outbreak in July
2003 more than 8000 cases and 774 deaths were attributed
to SARS worldwide (Kuiken et al., 2003). A new
coronavirus, termed the SARS coronavirus (SARS-CoV),
was isolated from patients with SARS (Drosten et al., 2003;
Ksiazek et al., 2003; Poutanen et al., 2003). Soon after the
disease was recognized, the ability to experimentally infect
and induce interstitial pneumonitis in cynomolgus macaques0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2004.09.030
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20892. Fax: +1 301 496 8312.
E-mail address: ksubbarao@niaid.nih.gov (K. Subbarao).with SARS-CoV was demonstrated, thus fulfilling Koch’s
postulates and confirming that SARS-CoV was the causa-
tive agent of SARS (Fouchier et al., 2003; Kuiken et al.,
2003). Efforts to develop an animal disease model for SARS
have continued. BALB/c mice have been established as a
good rodent model for the replication of SARS-CoV
(Subbarao et al., 2004) and viral replication has also been
demonstrated in ferrets and cats (Martina et al., 2003).
Although pigs and chickens could be experimentally
infected with SARS-CoV, these species did not support
efficient virus replication (Weingartl et al., 2004). In
addition to the importance of establishing the microbial
etiology of a disease, animal models are critical to the study
of disease pathogenesis and the evaluation of treatment and
control strategies. Non-human primates have been useful in
evaluating vaccines and studying disease pathogenesis for004) 8–15
Rapid Communication 9several respiratory viruses including influenza, respiratory
syncytial virus, and human parainfluenza viruses (Crowe et
al., 1993; Durbin et al., 2000; Murphy et al., 1982;
Rimmelzwaan et al., 2001; Skiadopoulos et al., 2002).
These studies demonstrated that the susceptibility of differ-
ent monkey species to specific respiratory viruses is
variable. However, assessment of the level of virus
replication in the respiratory tract of these models has been
very informative.
The primary purpose of this study was to identify the most
permissive non-human primate species that could serve as a
reproducible and informative model for the evaluation of
SARS vaccines and immunotherapy. We evaluated the level
of virus replication and serologic response to infection with
SARS-CoV in three species of Old World monkeys.Results
Comparison of level of replication of SARS-CoV in three
species of nonhuman primates
We first undertook a comparison of the level of
replication of SARS-CoV administered via the respiratory
route to three species of Old World monkeys (4 African
Green, 4 rhesus and 4 cynomolgus monkeys). Clinical signs
of the febrile respiratory illness that defined SARS in
humans or afebrile respiratory tract illness were not
observed in any of the monkeys following administration
of 106.3 tissue culture infectious doses (TCID50) of SARS
CoV. Rectal temperatures of all monkeys remained in the
normal range (98–102 8F) for the duration of the study with
the exception of one African Green monkey (AGM) that had
a fever of 105 8F on day 3.
The level of replication of SARS-CoV in the upper and
lower respiratory tract of monkeys of all the three species
detected from combined nose and throat (NT) swabs and
tracheal lavage (TL) samples is presented in Fig. 1. The
level of viral replication in AGMs was greater than that in
cynomolgus monkeys, which was greater than that in rhesus
monkeys. Mean peak virus titers in AGMs were 103.1 and
103 TCID50/ml in the upper and lower respiratory tract,
respectively (panels E and F).
Plasma, urine, and fecal specimens from rhesus monkeys
and AGMs did not yield infectious virus but viral genome
was detected by reverse-transcriptase polymerase chain
reaction (RT-PCR) from fecal samples of the four SARS-
infected AGMs between days 8 and 20 (data not shown).
Laboratory evaluations in AGMs revealed two findings that
were not observed in rhesus or cynomolgus monkeys and
were suggestive of systemic infection and may warrant
further investigation. First, the hemoglobin concentrations
and hematocrit of the four AGMs decreased by a mean of
25% by days 8–10 following infection and returned to
baseline by day 27. The total white blood cell and platelet
counts did not demonstrate a similar pattern. Second, liverenzyme elevations (alanine amino transferase and isocitrate
dehydrogenase) were noted in the serum of two AGMs with
peak levels at day 4 post-infection; these values returned to
baseline by day 27.
Serologic response to SARS-CoV infection
Serum IgG antibody titers against recombinant baculo-
virus-expressed spike (S) protein of SARS-CoV were
measured in an ELISA assay (Table 1). Four-fold rises in
titer were detected in all monkeys following primary
infection but titers in pre-infection (day 0) sera ranged from
1:640 to 1:2560, suggesting that although the ELISA assay
detected four-fold rises following infection, it also detected
some pre-existing cross-reactive antibodies.
All monkeys were seronegative (titer b 1:8) for SARS-
specific neutralizing antibodies (Nt Ab) prior to virus
administration (Table 1). The mean titers of Nt Ab achieved
on day 28 in the three species of monkeys correlated with
the levels of virus replication in the respiratory tract; the
mean titer was 1:27 in rhesus monkeys, 1:31 in cynomolgus
monkeys, and 1:57 in African Green monkeys (Table 1). In
our assay, the mean neutralizing antibody titer in post-
infection sera from mice was 1:25 to 1:49 (Subbarao et al.,
2004) and the titer in a convalescent human serum sample
was 1:71 (unpublished data). Serologic evidence of infec-
tion, defined as a four-fold rise in Nt Ab titer, was observed
in 4 of 4 rhesus, 3 of 4 cynomolgus, and 4 of 4 AGMs.
Virologic and histopathologic findings at necropsy in
SARS-CoV infected African Green monkeys
Although the study described above indicated that all
three species of monkeys were infected with SARS-CoV,
there were significant discrepancies between our findings
and published reports of cynomolgus macaques infected
with SARS-CoV; Kuiken et al. (2003) reported clinical
illness and pathologic evidence of disease in cynomolgus
macaques. We did not euthanize the monkeys in our first
study, so we were unable to determine whether there were
any histologic changes associated with virus replication. In
order to resolve these differences, we performed an addi-
tional study in six AGMs, where four AGMs received the
same dose (106.3 TCID50) of SARS-CoV by intranasal and
intratracheal administration and two were mock-infected.
Two infected and 1 mock-infected animal were euthanized
and necropsied on day 2 and the remaining two infected and
one mock-infected animals were euthanized and necropsied
on day 4. Combined NT swabs were collected daily and TL
fluids were collected every other day till the animals were
euthanized, so that we could determine how accurately NT
swabs and TL samples reflected the level of virus replication
in the lungs. At necropsy, trachea, nasal turbinates, and 12 to
14 samples from each animal’s lungs were assayed for virus
titration and histopathology and samples from the liver and
spleen were examined for histopathologic changes.
Fig. 1. SARS-CoV replication in the respiratory tract of monkeys. Mean titers of virus (expressed as log10 TCID50/ml of sample; y axis) detected on indicated
days (x axis) in the upper respiratory tract (left panels, A, C, and E, closed symbols) and lower respiratory tract (right panels, B, D, and F, open symbols) of
rhesus (panels A and B, x, w), cynomolgus (panels C and D,E,4), and African Green (panels E and F, n, 5) monkeys following intranasal and intratracheal
administration of 106 TCID50 of SARS-CoV. Error bars associated with each data point indicate standard error, and the dotted line indicates the lower limit of
detection of virus (100.5 TCID50/ml).
Rapid Communication10In three of four SARS-CoV-infected AGMs, virus titers
in TL samples did not accurately reflect the titer of virus
present in tracheal or lung tissue (Table 2) and consistently
higher titers of virus were seen in lung, tracheal, or nasal
turbinate tissue homogenates than in NT swabs or TL
samples (Table 2). Moderate (AGM ID #443) to high
(AGM ID #400) titers of virus were present in the tissue
samples from the right lung on day 2, but the detection of
virus was more patchy and titers were significantly lower
on day 4 (Table 2). Virus titers in samples from the right
lung were higher than in samples from the left lung,
presumably because the right main stem bronchus is
straighter and more of the intratracheally administered
virus inoculum reached the right lung. There was no
difference between the titer of virus in samples collectedfrom the hilar region compared to those from the periphery
of the lungs (data not shown).
Microscopic examination of lungs of AGMs sacrificed on
day 2 post-infection revealed focal interstitial mononuclear
inflammatory infiltrates (Fig. 2) and edema in the lung.
Immunohistochemical assays (IHC) showed focal distribu-
tion of viral antigens in tracheal and bronchiolar epithelial
cells, pneumocytes (Figs. 3A–C), and macrophages on day 2
post-infection. IHC with double staining confirmed that the
majority of SARS-CoV-antigen-positive cells were type I
pneumocytes (co-labeled with cytokeratin and not co-
labeled with surfactant, Fig. 4A) and some scattered
macrophages (co-labeled with antibodies to CD68, Fig.
4B). The degree of inflammation and the amount of viral
antigen were significantly reduced in the lungs of animals
Table 1
Serum neutralizing and SARS-S specific ELISA IgG antibody responses
following intranasal and intratracheal administration of SARS-CoVa
Monkey Serum antibody titer on indicated day
Neutralizing Ab ELISA Ab
Species ID # Day 0 Day 28 Day 0 Day 28
Rhesus 97 b1:8b 1:37c 1:640 1:10240
9R b1:8 1:18 1:640 1:2560
8V b1:8 1:17 1:640 1:2560
6K b1:8 1:36 1:2560 1:10240
Cynomolgus 18 b1:8 1:32 1:640 1:10240
1806 b1:8 b1:8 1:640 1:2560
396 b1:8 1:16 1:640 1:10240
972 b1:8 1:71 1:160 1:40960
African Green V130 b1:8 1:35 1:2560 1:40960
V131 b1:8 1:64 1:2560 1:10240
V240 b1:8 1:64 1:640 1:10240
V304 b1:8 1:64 1:640 1:10240
a Monkeys received 1 ml each of 106 TCID50 of SARS-CoV by intranasal
and intratracheal administration on day 0 and sera were collected before
virus administration and 28 days later.
b Sera were tested starting with a dilution of 1:8. Serum samples that did
not neutralize virus infectivity at the starting dilution were assigned a titer
of 1:4 in determining four-fold rises.
c Four-fold rises in titer are indicated in bold type.
Rapid Communication 11sacrificed 4 days post-infection compared to findings on day
2 post-infection (data not shown). Prominent histopatho-
logic changes and immunostaining were not observed in
liver and spleen on day 2 or day 4 post-infection.
Response of AGMs previously infected with SARS-CoV to
re-challenge
The ability of primary infection to prevent re-infection
was evaluated in the AGMs. The four AGMs from the first
study were challenged with the same dose (106.3 TCID50) of
SARS-CoV administered via the intratracheal and intranasal
route 2 months following primary infection. This study was
performed before we established that virus titer in tissue
homogenates exceeded titers seen in respiratory secretions,
so only NT swabs and TL were collected from these animals
following challenge. Virus replication was highly restrictedTable 2
Comparison of virus titers in NT swabs, TL fluids, and tissue samples collected
Monkey Sacrificed Virus titer in upper respiratory tractb
ID # on indicated
NT swab on days Nasal TL on
day post-





400 2 1.5 b0.5d 5.5 b0.5d
443 2 b0.5d b0.5d 3.7 3.2
420 4 1 3.0 2.2 b0.5d 4.0 b0.5d
568 4 1.5 1 2.0 b0.5d 3.7 b0.5d
a Four AGMs received 106.3 TCID50 of SARS-CoV by intranasal and intratrache
b Virus titers are expressed as log10 TCID50/ml from secretions and as log10 TCI
c Titers in lung are expressed as mean F standard error for 4–8 samples obtaine
d Virus was not detected; the lower limit of detection in tissue homogenates wasin the respiratory tract upon challenge; virus was not
isolated from the upper respiratory tract of any monkey
and was isolated at a single time point (day 2) at the lowest
detectable titer in the lower respiratory tract of 2 AGMs (ID
#240 and #304). The possibility that this low titer represents
residual virus inoculum cannot be ruled out. The AGMs had
measurable Nt Ab present prior to challenge, but two of the
AGMs (ID #131 and #240) developed a four-fold rise in
titer (data not shown) suggesting that, although virus
replication was restricted in the respiratory tract upon
challenge, at least two monkeys were re-infected.Discussion
We compared the responses of three species of Old
World monkeys to experimental infection with SARS-CoV
and established that although clinical illness was not present
in any of the three species, the rhesus, AGMs and all but one
cynomolgus monkey could be infected. SARS-CoV repli-
cated to a higher titer and for a longer time in the respiratory
tract of AGMs than in rhesus or cynomolgus monkeys, and
the Nt Ab response correlated with the level of virus
replication detected in the respiratory tract. Consistently
higher titers of virus were seen in tissue homogenates at
necropsy than in NT swabs or TL fluid collected before the
animals were sacrificed, indicating that more virus was
present in the tissues than in secretions. This observation is
consistent with the clinical finding that severe lung disease
can occur early in SARS cases, at a time when virus is not
easily detected in respiratory secretions (Peiris et al., 2003).
Histopathologic examination from AGM lungs revealed
interstitial pneumonitis in association with SARS-CoV on
day 2 that was resolving by day 4. IHC staining for SARS-
CoV antigens and double staining showed that tracheal and
bronchial epithelial cells and type 1 pneumocytes were
involved early in infection. These findings are consistent
with our findings in mice and hamsters infected with SARS-
CoV, where antigen is detected in epithelial cells early in
infection (Roberts et al., in press; Subbarao et al., 2004).at necropsy from the respiratory tract of AGMsa
Virus titer in lower respiratory tractb












3.5 7.2 F 0.29 8/8 2.8 F 0.78 3/4
4.2 4.0 F 0.36 8/8 2.9 F 0.41 5/6
b0.5d 2.5 2.3 F 0.36 5/8 2.2 F 0.36 3/6
b0.5d 4.0 3.3 F 0.47 7/8 V1.5 F 0d 0/6
al administration on day 0.
D50/g from 10% w/v tissue homogenates.
d from each lobe of the lung.
101.5 TCID50/g and in NT swabs and TL was 10
0.5 TCID50/ml.
Fig. 2. Histopathological findings in AGM lung 2 days post-infection.
Histopathologic examination of lungs shows edema and interstitial
mononuclear inflammatory infiltrates. Hematoxylin and eosin stain;
original magnification: 100.
Fig. 3. Immunohistochemical staining for SARS-CoV antigens in AGM
tissues obtained 2 days post-infection. SARS-CoV antigens stained red
were detected in: (A) tracheal epithelial cells; (B) bronchiolar epithelial
cells; (C) pneumocytes. Immunoalkaline phosphatase staining, naphthol
fast red substrate with light hematoxylin counterstain; original magnifica-
tion: A, B: 158; C: 100.
Fig. 4. Immunohistochemical double staining to localize SARS-CoV anti-
gens in AGM tissues obtained 2 days post-infection. (A) SARS-CoVantigen
and cytokeratin in pneumocytes in AGM lungs 2 days post-infection. Red
stain: SARS-CoV; brown stain: cytokeratin; original magnification: 158.
(B) SARS-CoV and CD68 antigens in alveolar macrophage. Red stain:
SARS-CoV; brown stain: CD68; original magnification:158. Double-stain
IHC with immunoalkaline phosphatase and peroxidase polymer.
Rapid Communication12Primary infection protected AGMs from re-infection with
SARS-CoV.
These findings are consistent with those reported by
Kuiken et al. and Haagmans et al., in appearance and
patchiness, though we see more evidence of pneumonitis at
an earlier time point post-infection than reported by Kuiken et
al. (2003) or Haagmans et al. (2004) (day 2 instead of day 6 or
4, respectively). Kuiken et al. (2003) also found that one of
fourmacaques did not have detectable virus in the lungs at day
6. The key difference that remains unresolved between our
findings and those of Kuiken et al. is that we did not observe
lethargy, skin rash, or respiratory distress in cynomolgus
macaques (or rhesus orAGMs) infectedwith theUrbani strain
of SARS-CoV. Kuiken et al. (2003) infected cynomolgus
monkeys by administration of a Hong Kong SARS-CoV
strain into the nose, trachea, and conjunctiva,while our studies
were done with the Urbani strain administered into the nose
and trachea. Possible reasons that could account for the
differences in our findings and those reported by Kuiken et al.
(2003) in cynomolgus monkeys are differences in the strains
Rapid Communication 13of SARS-CoV used and differences in the subspecies of
monkeys in the two studies. Both strains of SARS-CoV were
isolated from fatal human cases and subsequently underwent a
similar number of passages in Vero cells. However, it is
possible that the strain used in the studies of Kuiken et al. is
more virulent for cynomolgus monkeys; this question can be
resolved by evaluating both strains in parallel.
There are concerns about the risk of enhanced disease on
re-exposure to SARS, as has been described with feline
infectious peritonitis virus infection (FIPV) in cats, where
accelerated and enhanced disease can occur on re-exposure
to FIPV in seropositive cats (Pederson and Boyle, 1980;
Weiss and Scott, 1981a, 1981b). Infection of macrophages
by FIPV is believed to be important in the pathogenesis of
accelerated disease. SARS-CoV primarily infects epithelial
cells in the lungs of AGMs but there is evidence of infection
in some macrophages as well that warrants further study.
However, the lack of clinical illness and active viral rep-
lication on challenge of AGMs is reassuring. We followed
the AGMs for 2 months after challenge and saw no evidence
of enhanced disease and no evidence of virus replication in
the lungs, liver, kidneys, spleen, or intestines at necropsy 2
months following challenge. These observations are con-
sistent with our findings in mice and hamsters, where
primary infection with SARS-CoV confers resistance to
reinfection and we have not detected evidence of enhanced
disease upon re-exposure to SARS-CoV (Roberts et al., in
press; Subbarao et al., 2004).
We have carefully considered the optimal use of these
three non-human primate species in the context of other
available animal models for SARS including mice, hamsters,
and ferrets. Serologic data from our study confirm that non-
human primates will be useful for vaccine immunogenicity
studies (Gao et al., 2003) and our virologic data and
histopathologic findings indicate that AGMs can be used
for vaccine efficacy studies (Bukreyev et al., 2004). SARS-
CoV titers in lung tissue homogenates were high in one AGM
and moderately high in the other at day 2 but were sig-
nificantly lower in both animals sampled on day 4. An early
peak of viral replication, seen in the respiratory tract of
AGMs, has also been reported inmice (Subbarao et al., 2004),
ferrets, and cats (Martina et al., 2003). It is not entirely clear
how these kinetics compare with those in humans because the
only report of viral load in respiratory secretions of SARS
patients was based on samples from subjects whowere treated
with steroids and ribavirin (Peiris et al., 2003). AGMs support
replication of SARS-CoV, with associated evidence of pneu-
monitis for at least 2 days but both viral infection and
pneumonitis are patchy and not as consistent as the
corresponding findings in experimentally infected mice and
hamsters (Roberts et al., in press; Subbarao et al., 2004). The
animal-to-animal variability, rapid clearance of virus from the
lungs, and rapid resolution of pneumonitis in AGMs are
considerations that preclude this species from being the ideal
model for the evaluation of the efficacy of vaccines against
viral challenge.Materials and methods
Virus and cells
Drs. L. J. Anderson and T. G. Ksiazek from the Centers
for Disease Control and Prevention (CDC), Atlanta, GA
kindly provided the SARS-CoV (Urbani strain) used in this
study (Ksiazek et al., 2003). The virus was isolated and
passaged twice in Vero E6 cells at the CDC and was
passaged twice in Vero cells in our laboratory. The Vero
cells were maintained in OptiPro SFM (Invitrogen, Carls-
bad, CA). All in vitro manipulations with infectious virus
were performed inside a biosafety cabinet, in a biosafety
containment level 3 facility, and personnel wore powered air
purifying respirators (3M HEPA AirMate, Saint Paul, MN)
as previously described (Subbarao et al., 2004).
Virus titers in secretions and tissues were determined in
Vero cell monolayers as previously described (Subbarao et
al., 2004) and are expressed as TCID50/ml or TCID50/g and




The NIH Animal Care and Use Committee approved the
monkey studies that were carried out in an animal biosafety
level 3 facility. All personnel entering the facility wore
powered air-purifying respirators (3M HEPA AirMate, Saint
Paul, MN). Four juvenile African Green monkeys (Cerco-
pithecus atheiops or Chlorocebus sabeus), four rhesus
monkeys (Macaca mulata) and four cynomolgus monkeys
(Macaca fasicularis) were inoculated intranasally and
intratracheally with 1 ml of 106 TCID50 of SARS-CoV in
each site.
NT samples from the upper respiratory tract were
collected daily from day 0 (prior to inoculation) to day
10 and on days 12, 14, 20, 23, and 27 post-inoculation. TL
samples from the lower respiratory tract were collected on
days 2, 4, 6, 8, 10, 14, 20, and 27 post-inoculation. Feces,
plasma, and urine samples were collected on days 2, 4, 6,
8, 10, 14, 20, and 27 post-inoculation. Duplicate samples
were flash frozen and stored at 70 8C until all samples
were available for virus titration. NT, TL, plasma, urine and
fecal samples were assayed for presence of infectious
SARS-CoV. Piperacillin (Sigma Aldrich Co., St. Louis,
MO), gentamicin (Invitrogen, Grand Island, NY) and
amphotericin B (Quality Biological, Gaithersburg, MD)
were added to the tissue culture medium at final concen-
trations of 0.4, 0.1, 5 mg/L, respectively, when determining
virus titers from monkey samples.
Monkeys were observed daily for signs of clinical
illness from day 0 to day 10, and on days 12, 14, 20,
23, and 27 post-inoculation. Rectal temperatures of
monkeys were recorded, and blood was collected on
days 0, 2, 4, 6, 8, 10, 14, 20, and 28 for a complete
blood count and alanine amino transferase (ALT),
Rapid Communication14isocitrate dehydrogenase (ICD), and gamma glutamyl
transferase (GGT) levels.
To determine whether primary infection protected mon-
keys from subsequent challenge, AGMs were inoculated
intranasally and intratracheally with 106 TCID50 of SARS-
CoV 2 months after the end of the primary infection study.
NT and TL were collected and titered as described above for
primary infection.
The rhesus and cynomolgus monkeys were euthanized 2
months after primary infection and the AGMs were
euthanized 2 months following challenge infection and
tissue samples were obtained from liver, spleen, kidneys,
and lungs for virus isolation.
An additional study was undertaken in AGMs in order
to determine whether the replication of SARS-CoV was
associated with histopathologic changes in the lungs and to
compare the level of virus replication in lung tissue with
that seen in NT swabs and TL fluid. Four AGMs were
inoculated intranasally and intratracheally with 106 TCID50
of SARS-CoV, and two were mock infected with Leibovitz
15 medium (Invitrogen) on day 0. Two days later, two
SARS-CoV infected and one mock-infected AGM were
euthanized and the remaining two SARS-CoV infected and
one mock-infected AGM were euthanized on day four.
Monkeys were observed daily for signs of clinical illness,
rectal temperatures were recorded, and blood was collected
on days 0, 2, and 4 for a complete blood count and a
determination of the level of liver enzymes. NT swabs
were collected daily and TL fluids were collected every
other day till the animals were euthanized. At necropsy,
trachea, nasal turbinates, and tissue blocks of 1 cm3 from
the hilar and peripheral regions of each lobe of the lungs
were frozen and assayed for virus titration. Similar lung
tissue blocks were fixed in 2.5% glutaraldehyde for
electron microscopy and the remaining tissues were placed
in formalin for histopathologic examination. Additional
tissue samples that were collected for histopathologic
examination include liver, spleen, kidney, heart, bone
marrow, and intestines.
RNA extraction from fecal samples
Fecal samples from AGM and cynomolgus monkeys
were thawed and 0.1 to 0.2 g of feces was suspended in
sterile phosphate buffered saline for a final 10% w/v
solution. RNA was extracted as per manufacturer’s protocol
(Qiagen Viral RNA Kit, Valencia, CA) from clarified
supernatants and stored at 80 8C. Fecal samples from
rhesus monkeys were not tested.
Reverse transcriptase PCR for SARS-CoV
Reverse transcription and real-time PCR analysis was
performed using the Stratagene Brilliant Plus Two-Step
Quantitative RT-PCRCore Reagent Kit as per manufacturer’s
protocol on a MX4000 thermocycler (Stratagene, LaJolla,CA). Primers and TaqMan probe (synthesized by Qiagen)
were used to amplify and detect a small 70-bp fragment
located in the SARS CoV N-ORF (Accession number
AY278741). The sequences of the primers used were as
follows: forward: 5V-CCG AAG AGC TAC CCG ACG-3V;
reverse: 5V-GAA GTA CCA TCT GGG GCT GAG-3Vand
probe 5V-Hex-CTC TTT CAT TTT GCC GTC ACC ACC
AC-BHQ1-3V. Samples from which the 70-bp fragment was
consistently amplified in two or more independent assays
(each performed in duplicate or triplicate) were reported as
positive for detection of SARS-CoV viral RNA.
Neutralizing antibody assay
Serum samples were assayed for the presence of
neutralizing antibody in a microneutralization assay starting
with a dilution of 1:8. The serum dilution that completely
neutralized infectivity of 100 TCID50 of virus was
calculated by the method of Reed and Muench as described
previously (Subbarao et al., 2004). Serum samples that did
not neutralize virus infectivity at the starting dilution were
assigned a titer of 1:4 to determine four-fold rises in titer.
ELISA antibody assay
Serial four-fold dilutions of heat-treated sera were
assayed for the presence of IgG antibodies against the spike
(S) protein of SARS-CoV in an ELISA assay. Serum
dilutions beginning at 1:40 were applied to wells of
Immulon 1B plates (Dynex Technologies, Inc., Chantilly,
VA) that were coated with 40 ng per well of purified
recombinant baculovirus-expressed SARS S protein (Pro-
tein Sciences, Inc. Meridian, CT). The second antibody used
was rabbit anti-monkey IgG at a dilution of 1:30,000 (ICN,
Aurora, OH) and the ELISA was developed using alkaline
phosphatase-labeled goat anti-rabbit antibody at 1:8000
(ICN) followed by substrate. The ELISA antibody titer
recorded was the serum dilution at which the optical density
reading at 405 nm exceeded 0.2 and exceeded the reading
from wells that were not coated with antigen by two-fold.
Immunohistochemistry
A colorimetric immunoalkaline phosphatase IHC method
was used as previously described (Subbarao et al., 2004).
Double-stain IHC was performed by using peroxidase
polymer (DakoCytomation Inc., Carpinteria, CA) labeled
antibodies against cytokeratin, surfactant, or CD68, fol-
lowed by the mouse anti-SARS-CoV antibody labeled with
immunoalkaline phosphatase polymer.
Statistics
Log transformed virus titers were compared in a two-
tailed t test and statistical significance was assigned to
differences with P values b0.05.
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